Drug Profile
Lamivudine/zidovudine - Mylan Pharmaceuticals
Alternative Names: Lamivudine/zidovudine tablets - Mylan Pharmaceuticals; Lamivudine/zidovudine tablets for oral suspension - Mylan Pharmaceuticals; Zidovudine/lamivudine tablets - Mylan Pharmaceuticals; Zidovudine/lamivudine tablets for oral suspension - Mylan PharmaceuticalsLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Mylan Pharmaceuticals
- Class Antiretrovirals; Azides; Dideoxynucleosides; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Nucleoside reverse transcriptase inhibitors; RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered HIV-1 infections
Most Recent Events
- 28 Nov 2018 Lamivudine/zidovudine tablets and tablets for oral suspension not yet avaliable in USA for HIV-1 infections (Mylan website, November 2018)